Clinical trial NCT04023669: Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Official title: St. Jude ELIOT: Phase 1 Evaluation of LY2606368, a Molecularly-Targeted CHK1/2 Inhibitor Therapy, in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Brain Tumor
Brain Tumor, Recurrent
Brain Tumor, Refractory
Brain Tumor, Pediatric
Medulloblastoma
Medulloblastoma Recurrent
Medulloblastoma, Non-WNT/Non-SHH
Medulloblastoma, Non-WNT/Non-SHH, Group 3
Medulloblastoma, Non-WNT/Non-SHH, Group 4
Brain Cancer
CNS Cancer
CNS Tumor
CNS Neoplasm
Keywords: Brain Tumors in Adolescents
Brain Tumors in Children
Brain Tumors in Young Adults
CHK1/2 Inhibitor
Combination therapy
Indeterminate molecular subgroup
Medulloblastoma, Group 3
Medulloblastoma, Group 4
Medulloblastoma, G3/G4
Progressive brain tumor
Recurrent brain tumor
Refractory brain tumor
Sonic hedgehog
SHH Medulloblastoma
St. Jude Brain Tumor Studies
St. Jude Studies
St. Jude Treatment
Molecular
Molecular therapy
Lead sponsor: St. Jude Children's Research Hospital
Sponsor class: OTHER
Collaborators: name: Eli Lilly and Company
First posted: 2019-07-17
Enrollment: 21
Sex: ALL
Minimum age (years): 1
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: SJELIOT is a phase 1 trial that aims to explore the combination of prexasertib with established DNA-damaging agents used in medulloblastoma to evaluate tolerance and pharmacokinetics in recurrent or refractory disease. Additionally, a small expansion cohort will be incorporated into the trial at the combination MTD/RP2D (maximum tolerated dose/recommended phase two dose) to detect a preliminary efficacy signal.

Stratum A: Prexasertib and Cyclophosphamide

Primary Objectives

* To determine the safety and tolerability and estimate the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of combination treatment with prexasertib and cyclophosphamide in participants with recurrent/refractory Group 3 and Group 4 medulloblastoma and recurrent/refractory sonic hedgehog (SHH) medulloblastoma.
* To characterize the pharmacokinetics of prexasertib in combination with cyclophosphamide.

Secondary Objectives

* To estimate the rate and duration of objective response and progression free survival (PFS) associated with prexasertib and cyclophosphamide treatment in this patient population.
* To characterize the pharmacokinetics of cyclophosphamide and metabolites.

Stratum B: Prexasertib and Gemcitabine

Primary Objectives

* To determine the safety and tolerability and estimate the MTD/RP2D of combination treatment with prexasertib and gemcitabine in participants with recurrent/refractory Group 3 and Group 4 medulloblastoma.
* To characterize the pharmacokinetics of prexasertib in combination with gemcitabine.

Secondary Objectives

* To estimate the rate and duration of objective response and PFS associated with prexasertib and gemcitabine treatment in this patient population.
* To characterize the pharmacokinetics of gemcitabine and gemcitabine triphosphate (only at St. Jude Children's Research Hospital).

Detailed description: Participants will be stratified by the biological characteristics of their tumor to one of two treatment strata:

STRATUM A

* Combination Treatment: prexasertib and cyclophosphamide
* Patient population: Participants with recurrent/refractory Group 3 and Group 4 (G3/G4) medulloblastoma, recurrent/refractory sonic hedgehog (SHH) medulloblastoma and medulloblastoma participants with Indeterminate molecular subgroup

STRATUM B

* Combination Treatment: prexasertib and gemcitabine
* Patient population: Participants with recurrent/refractory Group 3 and Group 4 medulloblastoma

Participants with a diagnosis of G3/G4 medulloblastoma who qualify for both treatment strata will be assigned per slot availability as well as institutional PI preference. If slots are available in both stratum A and stratum B, patients will be assigned to the dose level nearest completion.

The Rolling 6 design will be used separately in each stratum to estimate the maximum tolerated dose (MTD) or recommended phase two dose (RP2D). Therapy will be administered in cycles of 28 days and may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.

Participants will receive doublet therapy in cycles of 28 days. The dose-limiting toxicity (DLT)-evaluation period will consist of the first cycle until day 1 criteria of cycle 2 has been met. Participants will be evaluated at least once a week during the DLT-evaluation period and at regular intervals thereafter. Standard tests (i.e. physical exams, blood tests, and disease evaluations) will be undertaken at regular intervals. Research-associated evaluations (i.e. pharmacokinetic studies, etc.) will also be carried out during therapy. Treatment may be continued for up to 2 years in the absence of disease progression or unacceptable toxicity.

Eligibility criteria: Inclusion Criteria: Screening Phase

* Participants with recurrent, refractory, or progressive medulloblastoma.
* Age ≥ 1 year and \< 25 years at the time of screening.
* Participants and/or guardian can understand and is willing to sign a written informed consent document according to institutional guidelines.

Exclusion Criteria: Screening Phase

* Previous exposure to any CHK1 inhibitor.
* Participants with a history of clinically significant, uncontrolled heart disease and/or repolarization abnormalities.
* Participants with any history of QTc prolongation (i.e. QTc interval of \> 480 msec).

Inclusion Criteria: Strata A and B

* Participant must be ≥1 year and \<25 years of age at time of screening.
* Participant must have recurrent, progressive or refractory Group 3/Group 4 or SHH medulloblastoma (per central pathology confirmation of primary tissue and/or relapsed tissue). Central pathology review previously completed at St. Jude Children's Research Hospital using equivalent methods can be used for enrollment. Note: Group 3/Group 4 may be referred to as Non-WNT Non-SHH (NWNS) in pathology reports. Medulloblastoma patients with indeterminate molecular subgroup after central pathology review are eligible for enrollment on stratum A.
* Participant must have measurable or evaluable disease as defined in the protocol.
* Participant must have received their last dose of myelosuppressive anticancer chemotherapy at least 3 weeks prior to study enrollment.
* Participants must have had their last fraction of radiation (including CSI) at least 4 weeks prior to study enrollment. Participants who received radiation therapy for palliation must have had their last fraction of radiation at least 2 weeks prior to study enrollment.

  -- Note: Participants must have relapsed with recurrent, progressive or refractory disease after any prior radiation therapy that is not considered palliative. Palliative radiation therapy is defined as local small port RT to alleviate and/or palliate symptoms. (CSI, whole brain RT, large field/port RT, or large field/port multilevel spinal RT will not be considered palliative at any dose.)
* Participant who are receiving corticosteroids must be on a stable or decreasing dose for at least 1 week prior to enrollment with no plans for escalation.
* Participant must have a Lansky (≤ 16 years) or Karnofsky (\> 16 years) performance score of ≥50 and, in the opinion of the investigator, a minimum life expectancy of at least 6 weeks.

  -- Note: Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
* Participant must have adequate bone marrow and organ function as defined as:

  * ANC ≥ 1.0 x 10\^9/L without growth factor support within 7 days
  * Platelet count ≥ 75x 10\^9/L without support of a platelet transfusion within 7 days
  * Hemoglobin ≥8.0 g/dL without support of a blood transfusion within 7 days
  * Potassium, total calcium (corrected for serum albumin), magnesium, sodium and phosphorus within institutional normal limits or corrected to within normal limits with supplements before first dose of study medication
  * Serum creatinine ≤ the maximum serum creatinine based on age/gender: Age: 1 to \< 2 years; maximum serum creatinine (mg/dL): 0.6 (male, female); Age: 2 to \< 6 years; maximum serum creatinine (mg/dL): 0.8 (male, female); Age: 6 to \< 10 years; maximum serum creatinine (mg/dL): 1 (male, female); Age: 10 to \< 13 years; maximum serum creatinine (mg/dL): 1.2 (male, female); Age: 13 to \< 16 years; maximum serum creatinine (mg/dL): 1.5 (male), 1.4 (female); Age :≥ 16 years; maximum serum creatinine (mg/dL): 1.7 (male), 1.4 (female).
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN. For the purposes of this study the ULN of ALT and AST is 45 U/L.
  * Total bilirubin ≤ ULN; or if \> ULN then direct bilirubin ≤ 1.5 x ULN
* Female participants of childbearing age must have a negative pregnancy test at the time of enrollment.
* Participants of childbearing or child fathering potential must be willing to use medically acceptable form of birth control during treatment and for 16 weeks after stopping treatment.
* Participants and/or guardian have the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.

Exclusion Criteria: Strata A and B

* Participant who is receiving any other investigational agents.
* Participants with other clinically significant medical disorders (i.e. serious infections or significant cardiac, pulmonary, hepatic, psychiatric, or other organ dysfunction) that could compromise their ability to tolerate protocol therapy or would interfere with the study procedures or results.
* Participant with a history of clinically significant, uncontrolled heart disease and/or repolarization abnormalities as documented by a standard 12-lead ECG.
* Shortening fraction of \<27% by ECHO or ejection fraction of \<50% by gated radionuclide study.
* Prior history of QTc prolongation or QTc interval of \> 480 msec.
* Female participants who are breastfeeding a child.
* Participants are excluded if unable to comply with guidelines listed in appendix I.

Primary outcomes:
measure: Estimate the Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of each doublet by stratum
timeFrame: 1 month after start of prexasertib and cyclophosphamide or gemcitabine treatment
measure: To determine the safety and tolerability of combination treatment with prexasertib and cyclophosphamide or gemcitabine.
timeFrame: Up to 2 years after start of prexasertib and cyclophosphamide or gemcitabine treatment
measure: To characterize the area under the concentration-time curve (AUC0-∞) of prexasertib in combination with cyclophosphamide or gemcitabine.
timeFrame: prexasertib and cyclophosphamide or gemcitabine treatment course 1 days 2 through 7
measure: To characterize the systemic clearance (CL) of prexasertib in combination with cyclophosphamide or gemcitabine.
timeFrame: prexasertib and cyclophosphamide or gemcitabine treatment course 1 days 2 through 7
Secondary outcomes:
measure: Rate of objective response (complete or partial response) by stratum
timeFrame: Up to 1 year after completion of prexasertib and cyclophosphamide or gemcitabine treatment
measure: Duration of objective response by stratum
timeFrame: Up to 1 year after completion of prexasertib and cyclophosphamide or gemcitabine treatment
measure: Progression-free survival for patients treated with prexasertib and cyclophosphamide or gemcitabine
timeFrame: Up to 3 years from diagnosis
measure: To characterize the area under the concentration-time curve (AUC0-24h) of cyclophosphamide.
timeFrame: prexasertib and cyclophosphamide treatment course 1, days 1 and 2
measure: To characterize the systemic clearance (CL) of cyclophosphamide.
timeFrame: prexasertib and cyclophosphamide treatment course 1, days 1 and 2
measure: To characterize the area under the concentration-time curve (AUC0-24h) of 4-hydroxy-cyclophosphamide.
timeFrame: prexasertib and cyclophosphamide treatment course 1, days 1 and 2
measure: To characterize the area under the concentration-time curve (AUC0-24h) of carboxyethylphosphoramide mustard.
timeFrame: prexasertib and cyclophosphamide treatment course 1, days 1 and 2
measure: To characterize the area under the concentration-time curve (AUC0-4h) of gemcitabine.
timeFrame: prexasertib and gemcitabine treatment course 1, day 1.
measure: To characterize the systemic clearance (CL) of gemcitabine.
timeFrame: prexasertib and cyclophosphamide treatment course 1, day 1
measure: To characterize the area under the concentration-time curve (AUC0-4h) of gemcitabine triphosphate (only at St. Jude Children's Research Hospital).
timeFrame: prexasertib and cyclophosphamide treatment course 1, day 1
Other outcomes:
Locations:
city: Memphis
country: United States
facility: St. Jude Children's Research Hospital
state: Tennessee
Study officials:
affiliation: St. Jude Children's Research Hospital
name: Giles W. Robinson, MD
role: PRINCIPAL_INVESTIGATOR
References: